Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Amgen Inc. is conducting a long-term extension study titled ‘A Multicenter, Long-term, Randomized, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjögren’s Syndrome (SS).’ The study aims to assess the safety and tolerability of dazodalibep, a drug intended for treating Sjögren’s Syndrome, over an extended period.
The intervention being tested is dazodalibep, administered intravenously. It is designed to provide therapeutic benefits for patients with Sjögren’s Syndrome by continuing treatment from previous trials.
The study is interventional, with a randomized allocation and a parallel intervention model. It employs double masking, meaning both participants and investigators are unaware of the treatment assignments. The primary purpose is treatment-focused.
The study began on February 25, 2025, with the last update submitted on June 25, 2025. These dates are crucial as they mark the study’s progression and the latest information available to the public.
This update could influence Amgen’s stock performance positively by showcasing the company’s commitment to advancing treatments for autoimmune diseases. It may also impact investor sentiment favorably, especially if the results demonstrate significant safety and tolerability improvements. Competitors in the autoimmune treatment space will be closely monitoring these developments.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.